Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesOphthalmology/OptometryAllCareAdvantage intravitreal Anti‑VEGF Prior Auth…
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 132.1

    Anti-VEGF antibodies (intravitreal) prior authorization

    Customize your policy alerts

    Sign up for allcareadvantage Policy 132.1 alerts

    Get alerted when Policy 132.1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, and renewal requirements for intravitreal anti-VEGF antibody agents for retinal diseases for AllCare Advantage members.

    Policy Summary
    Payerallcareadvantage
    PolicyAnti-VEGF antibodies (intravitreal) prior authorization
    Policy CodePolicy 132.1
    Change TypeRoutine review — no material changes
    Effective DateMar 31, 2025
    Last ReviewMar 31, 2025
    Next Review DateMar 31, 2027
    Key ActionObtain prior authorization and document patient age ≥18, retinal diagnosis, retinal specialist provider, and required prior treatment failures or contraindications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 12 monthsApproval length
    ≥18Minimum age
    6Agents included
    Positive response requiredRenewal condition

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy

    Covered when the following sequence of criteria is met as applicable to the requested agent:

    Agent-specific prior failure or contraindication requirements: For ranibizumab: documentation of prior treatment failure or contraindication to bevacizumab is required. For aflibercept: documentation of prior treatment failure or contraindication to bevacizumab and ranibizumab is required. For aflibercept HD or faricimab: documentation of prior treatment failure or contraindication to bevacizumab, ranibizumab, and aflibercept is required.

    If required prior failures/contraindications are not documented, deny

    Approval: When prior criteria are met, approve therapy for up to 12 months; quantity limits apply per eye12 months

    Coverage limited to preferred formulary biosimilar agent(s) where applicable and available

    Renewal Therapy

    Renewal covered when the following are met:

    Renewal prerequisites: Member met the initial prior-authorization criteria AND there is chart documentation supporting a positive clinical response to the requested treatment

    If a positive response is not documented, deny renewal

    Coverage of intravitreal anti-VEGF therapy is subject to formulary preference: when a biosimilar or preferred formulary agent is applicable and available, coverage will be limited to that agent. The policy explicitly states there are no evidence‑based criteria to select among anti‑VEGF drugs and that real‑world choice is driven primarily by medication cost and insurance approval; therefore, prior authorization decisions will reflect formulary preference and biosimilar availability where indicated. (Approval lengths and quantity limits apply as described elsewhere in the policy.)

    Requests will be denied if required documentation or eligibility elements are missing. Specifically, the request must document the member is ≥18 years, that the injection is requested by a retinal specialist (vitreoretinal surgeon or vitreoretinal specialist), and that the medical record supports a retinal diagnosis for which anti‑VEGF therapy is indicated. For agent‑specific approvals, documentation must also show the required prior treatment failures or contraindications (e.g., prior failure/contraindication to bevacizumab for ranibizumab; to bevacizumab and ranibizumab for aflibercept; and to bevacizumab, ranibizumab, and aflibercept for aflibercept HD or faricimab). If these elements are not provided, the request does not meet criteria and will be denied or forwarded to physician review per policy.

    Coding and Included Agents

    Included anti-VEGF agentsNDC | mixed
    BevacizumabAgent included in criteria
    RanibizumabLucentis, Byooviz, Cimerli — agent included in criteria
    AfliberceptEylea, Yesafili, Opuviz, Ahzantive — agent included in criteria
    Aflibercept (Eylea HD)Agent included in criteria
    FaricimabVabysmo — agent included in criteria

    Provider Actions, Documentation & Step Therapy

    Prior Authorization

    Prior authorization required; approval up to 12 months

    Prior authorization is required for intravitreal anti‑VEGF therapy; coverage is limited to preferred formulary biosimilar agent(s) where applicable and available. When criteria are met, approvals are issued for up to 12 months.

    Step Therapy

    Step/failure hierarchy required for agent selection

    Approval of a requested agent requires documentation of prior treatment failure or a contraindication to earlier, preferred agents in a stepwise hierarchy: bevacizumab first, then ranibizumab, then aflibercept, then aflibercept HD or faricimab as applicable to the requested agent.

    • Ranibizumab: documentation of prior failure or contraindication to bevacizumab is required.
    • Aflibercept: documentation of prior failure or contraindication to bevacizumab and ranibizumab is required.
    • Aflibercept HD or Faricimab: documentation of prior failure or contraindication to bevacizumab, ranibizumab, and aflibercept is required.
    Documentation Required

    Required documentation to support request

    Submit documentation that supports age, diagnosis, provider specialty, prior treatments, and for renewals, response to treatment. Documentation must show the member is ≥18, that a retinal diagnosis indicates anti‑VEGF therapy, that the administering provider is a retinal specialist, and any required prior treatment failures or contraindications.

    • Patient age (≥18 years).
    • Retinal diagnosis for which anti‑VEGF therapy is indicated.
    • Administering provider specialty (vitreoretinal surgeon or vitreoretinal specialist).
    • Documentation of prior treatment failure or contraindication to required prior agents as applicable.
    • For renewals: chart documentation of a positive clinical response.
    Prior Authorization

    Administering provider must be a retinal specialist

    Requests for intravitreal injection must be submitted by a retinal specialist (vitreoretinal surgeon or vitreoretinal specialist); requests by non‑retinal specialists will be denied.

    Note

    Minimum age ≥18 years (under 18 forwarded to MD)

    Members must be at least 18 years old for initial eligibility; requests for members under 18 are forwarded to a medical director for review or do not meet criteria.

    Denial Risk

    Diagnosis must support indication; otherwise deny

    If submitted documentation does not support a retinal diagnosis for which anti‑VEGF therapy is indicated, the request will be denied.

    Denial Risk

    Denied if prior‑failure/contraindication documentation missing

    If documentation does not show the required prior treatment failure(s) or contraindication(s) to the specified prior agents for the requested drug, the request will be denied.

    • Lack of documented failure or contraindication to bevacizumab will result in denial for ranibizumab requests.
    • Lack of documented failure or contraindication to bevacizumab and ranibizumab will result in denial for aflibercept requests.
    • Lack of documented failure or contraindication to bevacizumab, ranibizumab, and aflibercept will result in denial for aflibercept HD or faricimab requests.
    Denial Risk

    Renewal requires documented positive clinical response

    For renewal requests, the chart must document a positive clinical response to the requested treatment; absence of such documentation will result in denial.

    • Renewal requires that the member met initial criteria and that a positive clinical response is documented.
    • If positive response is not documented, the renewal is denied.

    Background

    Vascular endothelial growth factor (VEGF) inhibitors are administered intravitreally to reduce macular edema and improve vision by decreasing vascular permeability. Multiple anti‑VEGF agents are used clinically — including bevacizumab, ranibizumab, aflibercept, faricimab, and ranibizumab‑nuna — and have been shown in observational studies and randomized trials to be effective and generally well tolerated for retinal diseases. The policy notes ranibizumab is the only agent FDA‑approved for myopic choroidal neovascularization, while other agents may be used off‑label; overall coverage decisions are influenced by formulary preference, biosimilar availability, and insurance approval.

    Definitions

    Anti-VEGF antibodies — definition and typical indications
    DefinitionIntravitreal medications that inhibit vascular endothelial growth factor (VEGF) used to treat retinal diseases such as neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion, and myopic choroidal neovascularization (CNV).
    Typical included agentsBevacizumab; Ranibizumab (Lucentis, Byooviz, Cimerli); Aflibercept (Eylea, Yesafili, Opuviz, Ahzantive); Aflibercept (Eylea HD); Faricimab (Vabysmo).
    Common indicationsNeovascular AMD, diabetic macular edema (DME), retinal vein occlusion, and myopic CNV (anti-VEGF therapy is first-line for myopic CNV; ranibizumab is the only FDA‑approved agent for this indication).
    Mechanism summaryReduce macular edema and improve vision by decreasing vascular permeability through inhibition of VEGF activity in the retina.
    Coverage noteCoverage is limited to preferred formulary biosimilar agent(s) where applicable and available per policy.
    Retinal specialist — definition and provider requirement
    DefinitionA retinal specialist is a vitreoretinal surgeon or vitreoretinal specialist who performs intravitreal injections and retinal disease management.
    Provider requirementIntravitreal anti‑VEGF therapy requests must be submitted by a retinal specialist (vitreoretinal surgeon or vitreoretinal specialist); requests by non‑retinal specialists will be denied.
    Relation to prior authorizationDocumentation of the provider specialty (retinal specialist) is required for prior authorization and for initial eligibility determination.
    Practical implicationIf the submitting provider is not a vitreoretinal specialist, the request will be denied or forwarded per policy review procedures.
    Policy Summary
    Payerallcareadvantage
    PolicyAnti-VEGF antibodies (intravitreal) prior authorization
    Policy CodePolicy 132.1
    Change TypeRoutine review — no material changes
    Effective DateMar 31, 2025
    Last ReviewMar 31, 2025
    Next Review DateMar 31, 2027
    Key ActionObtain prior authorization and document patient age ≥18, retinal diagnosis, retinal specialist provider, and required prior treatment failures or contraindications.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Included AgentsProvider Actions, Documentation & Step TherapyBackgroundDefinitions